TY  - JOUR
AU  - Sewell, Josie
AU  - Pan, Edward
AU  - B. Mella, Divya
PY  - 2018
DA  - 2018/11/01
TI  - A Case Series of Temozolomide in the Management of Refractory Prolactinomas
JO  - OBM Neurobiology
SP  - 014
VL  - 02
IS  - 04
AB  - Objective: To report three cases of refractory prolactinomas treated with Temozolomide (TMZ).
Background: Prolactinomas account for 40% of pituitary adenomas. Dopamine agonists (DA) are the first line of treatment followed by surgical resection and radiation. TMZ is an oral chemotherapeutic agent used in gliomas, which has been given to patients with prolactinomas refractory to conventional treatments.
Methods: Retrospective chart review was conducted for refractory prolactinoma patients treated between 2008 and 2017 at UT Southwestern Medical Center (UTSW). Three patients with refractory prolactinomas received oral TMZ at UTSW. 
Results: All three patients demonstrated improvement in symptoms upon TMZ treatment, markedly decreased serum prolactin levels (SPRL), as well as radiographic decrease in tumor size.  
Conclusion: TMZ is well tolerated and is a potentially effective treatment for refractory prolactinomas.
SN  - 2573-4407
UR  - https://doi.org/10.21926/obm.neurobiol.1804014
DO  - 10.21926/obm.neurobiol.1804014
ID  - Sewell2018
ER  -